Silihan lan utang jangka dawa perusahaan Asensus Surgical, Inc. (ASXC)

Asensus Surgical, Inc. (ASXC) generates revenue through the sale and leasing of Senhance robotic systems for AI-powered minimally invasive interventions. Patents for digital vision and the complexity of certification create significant barriers to entry for competitors. This debt valuation chart, serving as an assessment tool, shows a value of 0.00. Meanwhile, Asensus Surgical, Inc. (ASXC) maintains a sufficient liquidity buffer despite the slow adoption of its systems in clinics.

For Asensus Surgical, Inc. (ASXC), analyzing long-term liabilities is critical during a period of clinic capital expenditures on robotics. This metric aggregates all borrowed funds with a maturity exceeding one year, reflecting the overall debt load. The trajectory of long-term debt determines the company's ability to finance expansion without the risk of default. An increase in this indicator signals rising debt service costs, while a stable trend confirms the resilience of the business model during cyclical declines in equipment sales.